Logo image of FGEN

FIBROGEN INC (FGEN) Stock Fundamental Analysis

NASDAQ:FGEN - Nasdaq - US31572Q8087 - Common Stock - Currency: USD

0.7059  -0.07 (-8.61%)

After market: 0.6579 -0.05 (-6.8%)

Fundamental Rating

2

FGEN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. FGEN may be in some trouble as it scores bad on both profitability and health. FGEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FGEN had negative earnings in the past year.
In the past year FGEN has reported a negative cash flow from operations.
In the past 5 years FGEN always reported negative net income.
FGEN had negative operating cash flow in 4 of the past 5 years.
FGEN Yearly Net Income VS EBIT VS OCF VS FCFFGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

FGEN's Return On Assets of -46.06% is in line compared to the rest of the industry. FGEN outperforms 49.20% of its industry peers.
Industry RankSector Rank
ROA -46.06%
ROE N/A
ROIC N/A
ROA(3y)-50.91%
ROA(5y)-36.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FGEN Yearly ROA, ROE, ROICFGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

The Gross Margin of FGEN (76.87%) is better than 85.61% of its industry peers.
In the last couple of years the Gross Margin of FGEN has declined.
FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.8%
GM growth 5YN/A
FGEN Yearly Profit, Operating, Gross MarginsFGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

1

2. Health

2.1 Basic Checks

FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FGEN has more shares outstanding
The number of shares outstanding for FGEN has been increased compared to 5 years ago.
The debt/assets ratio for FGEN is higher compared to a year ago.
FGEN Yearly Shares OutstandingFGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
FGEN Yearly Total Debt VS Total AssetsFGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

FGEN has an Altman-Z score of -10.26. This is a bad value and indicates that FGEN is not financially healthy and even has some risk of bankruptcy.
FGEN has a worse Altman-Z score (-10.26) than 74.07% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.26
ROIC/WACCN/A
WACC7.17%
FGEN Yearly LT Debt VS Equity VS FCFFGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.28 indicates that FGEN should not have too much problems paying its short term obligations.
FGEN has a worse Current ratio (1.28) than 84.37% of its industry peers.
FGEN has a Quick Ratio of 1.16. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.16, FGEN is doing worse than 84.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.16
FGEN Yearly Current Assets VS Current LiabilitesFGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

FGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.02%, which is quite impressive.
The Revenue has grown by 16.14% in the past year. This is quite good.
Measured over the past years, FGEN shows a decrease in Revenue. The Revenue has been decreasing by -7.05% on average per year.
EPS 1Y (TTM)58.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.31%
Revenue 1Y (TTM)16.14%
Revenue growth 3Y-5.72%
Revenue growth 5Y-7.05%
Sales Q2Q%15.45%

3.2 Future

FGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.04% yearly.
The Revenue is expected to grow by 10.52% on average over the next years. This is quite good.
EPS Next Y70.86%
EPS Next 2Y35.43%
EPS Next 3Y23.02%
EPS Next 5Y15.04%
Revenue Next Year7.68%
Revenue Next 2Y0.3%
Revenue Next 3Y2.62%
Revenue Next 5Y10.52%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FGEN Yearly Revenue VS EstimatesFGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
FGEN Yearly EPS VS EstimatesFGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FGEN Price Earnings VS Forward Price EarningsFGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FGEN Per share dataFGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

FGEN's earnings are expected to grow with 23.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.43%
EPS Next 3Y23.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIBROGEN INC

NASDAQ:FGEN (2/21/2025, 8:17:55 PM)

After market: 0.6579 -0.05 (-6.8%)

0.7059

-0.07 (-8.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners56.63%
Inst Owner Change-21.34%
Ins Owners0.52%
Ins Owner Change-0.41%
Market Cap71.13M
Analysts80
Price Target10.2 (1344.96%)
Short Float %2.91%
Short Ratio2.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.17%
Min EPS beat(2)45.36%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)21.95%
Min EPS beat(4)-31.49%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)13.61%
EPS beat(12)7
Avg EPS beat(12)1.16%
EPS beat(16)9
Avg EPS beat(16)536.76%
Revenue beat(2)2
Avg Revenue beat(2)36.95%
Min Revenue beat(2)30.67%
Max Revenue beat(2)43.24%
Revenue beat(4)3
Avg Revenue beat(4)22.94%
Min Revenue beat(4)-31.61%
Max Revenue beat(4)49.47%
Revenue beat(8)7
Avg Revenue beat(8)21.91%
Revenue beat(12)8
Avg Revenue beat(12)12.52%
Revenue beat(16)9
Avg Revenue beat(16)2.8%
PT rev (1m)0%
PT rev (3m)1566.67%
EPS NQ rev (1m)36.36%
EPS NQ rev (3m)59.22%
EPS NY rev (1m)9.09%
EPS NY rev (3m)21.57%
Revenue NQ rev (1m)23.43%
Revenue NQ rev (3m)-20.44%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS1.79
BVpS-2.42
TBVpS-2.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.87%
FCFM N/A
ROA(3y)-50.91%
ROA(5y)-36.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.8%
GM growth 5YN/A
F-Score2
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.88%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.16
Altman-Z -10.26
F-Score2
WACC7.17%
ROIC/WACCN/A
Cap/Depr(3y)198.23%
Cap/Depr(5y)127.93%
Cap/Sales(3y)14.02%
Cap/Sales(5y)9.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.31%
EPS Next Y70.86%
EPS Next 2Y35.43%
EPS Next 3Y23.02%
EPS Next 5Y15.04%
Revenue 1Y (TTM)16.14%
Revenue growth 3Y-5.72%
Revenue growth 5Y-7.05%
Sales Q2Q%15.45%
Revenue Next Year7.68%
Revenue Next 2Y0.3%
Revenue Next 3Y2.62%
Revenue Next 5Y10.52%
EBIT growth 1Y66.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.26%
EBIT Next 3Y20.07%
EBIT Next 5Y11.92%
FCF growth 1Y32.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.18%
OCF growth 3YN/A
OCF growth 5YN/A